21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
21.10.Z - Manufacture of basic pharmaceutical products
46.45.Z - Wholesale trade of perfumes and cosmetics
46.46.Z - Wholesale trade of pharmaceutical and medical products
47.73.Z - Retail sale of pharmaceutical products
47.74.Z - Retail sale of medical and orthopedic products
47.75.Z - Retail sale of cosmetics and toiletries
70.22.Z - Head office activities and management consultancy
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.11.Z - Scientific research and development activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0,1 | 0 | -0,2 | -680 |
EBITDA | 0,8 | 1 | 0,9 | -5,1 |
Short time liabilities | 1,4 | 0,2 | 0,2 | -25,9 |
Equity capital | 7,6 | 7,6 | 7,4 | -2 |
Operating profit (EBIT) | -0,1 | 0 | -0,2 | -586,4 |
Assets | 17,1 | 14,8 | 13,6 | -8,1 |
Net profit (loss) | -0,1 | 0 | -0,2 | -680 |
Cash | 0,6 | 0,1 | 0 | -89,9 |
Net income from sale | 0,5 | 0,2 | 0,4 | 57,7 |
Liabilities and provisions for liabilities | 9,5 | 7,2 | 6,2 | -14,4 |
Working assets | 1,4 | 1 | 0,8 | -24,7 |
Depreciation | 0,9 | 1 | 1,1 | 13,7 |
% | % | % | p.p. | |
Profitability of capital | -1,7 | 0,4 | -2,1 | -2,5 |
Equity capital to total assets | 44,2 | 51,2 | 54,6 | 3,4 |
Gross profit margin | -24,2 | 10,7 | -39,4 | -50,1 |
EBITDA Margin | 146,9 | 396,7 | 238,6 | -158,1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 1003 | 342 | 161 | -181 |
Current financial liquidity indicator | 0.17259252071380615 | 0.17746511101722717 | 0.14871861040592194 | -0,1 |
Net dept to EBITDA | 0.43756669759750366 | 0.40670743584632874 | 0.1169908195734024 | -0,3 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane